The U.S. Food and Drug Administration has approved Krystexxa (pegloticase) to treat gout in adults who do not respond to, or who cannot tolerate, conventional therapy.
As we have discussed before, gout is caused by the build-up of uric acid in the blood, which turns into monosodium urate crystals which lodge in the joints and/or soft tissues of the body. When your own body's defenses fight these crystals, inflammation and pain can result.
Gout is more prevalent in people who are obese, have high blood pressure, high cholesterol, and diabetes. It occurs mostly in men or in women after menopause. Also at risk to have gout attacks are people who have kidney disease.
“About 3 percent of the three million adults who suffer from gout are not helped by conventional therapy. This new drug offers an important new option for them,” said Badrul Chowdhury, M.D., director of the Division of Pulmonary, Allergy, and Rheumatology Products in the FDA’s Center for Drug Evaluation and Research.
For patients with gout, the conventional therapy is to receive drugs that lower the amount of uric acid in the blood, as, for example, the xanthine oxidase inhibitors Zyloprim (allopurinol) and Uloric (febuxostat).
Krystexxa is an enzyme that lowers uric acid levels by metabolizing it into a harmless chemical that is excreted in the urine. The drug is administered to patients every two weeks as an intravenous infusion.
Krystexxa is being approved with a Risk Evaluation and Mitigation Strategy that includes a medication guide for patients and materials for healthcare providers to communicate the risk of severe infusion and allergic reactions.
Krystexxa is manufactured by Savient Pharmaceuticals Inc. of East Brunswick, N.J.Wednesday, December 11, 2013
Treating Gout - FDA Releases New Drug Krystexxa
I like to keep an eye out for new developments for treating gout, especially when there are new options. If you have used this new drug, post a comment below letting us know your opinion. Thanks . . . Renée
The U.S. Food and Drug Administration has approved Krystexxa (pegloticase) to treat gout in adults who do not respond to, or who cannot tolerate, conventional therapy.
As we have discussed before, gout is caused by the build-up of uric acid in the blood, which turns into monosodium urate crystals which lodge in the joints and/or soft tissues of the body. When your own body's defenses fight these crystals, inflammation and pain can result.
Gout is more prevalent in people who are obese, have high blood pressure, high cholesterol, and diabetes. It occurs mostly in men or in women after menopause. Also at risk to have gout attacks are people who have kidney disease.
“About 3 percent of the three million adults who suffer from gout are not helped by conventional therapy. This new drug offers an important new option for them,” said Badrul Chowdhury, M.D., director of the Division of Pulmonary, Allergy, and Rheumatology Products in the FDA’s Center for Drug Evaluation and Research.
For patients with gout, the conventional therapy is to receive drugs that lower the amount of uric acid in the blood, as, for example, the xanthine oxidase inhibitors Zyloprim (allopurinol) and Uloric (febuxostat).
Krystexxa is an enzyme that lowers uric acid levels by metabolizing it into a harmless chemical that is excreted in the urine. The drug is administered to patients every two weeks as an intravenous infusion.
Krystexxa is being approved with a Risk Evaluation and Mitigation Strategy that includes a medication guide for patients and materials for healthcare providers to communicate the risk of severe infusion and allergic reactions.
Krystexxa is manufactured by Savient Pharmaceuticals Inc. of East Brunswick, N.J.
The U.S. Food and Drug Administration has approved Krystexxa (pegloticase) to treat gout in adults who do not respond to, or who cannot tolerate, conventional therapy.
As we have discussed before, gout is caused by the build-up of uric acid in the blood, which turns into monosodium urate crystals which lodge in the joints and/or soft tissues of the body. When your own body's defenses fight these crystals, inflammation and pain can result.
Gout is more prevalent in people who are obese, have high blood pressure, high cholesterol, and diabetes. It occurs mostly in men or in women after menopause. Also at risk to have gout attacks are people who have kidney disease.
“About 3 percent of the three million adults who suffer from gout are not helped by conventional therapy. This new drug offers an important new option for them,” said Badrul Chowdhury, M.D., director of the Division of Pulmonary, Allergy, and Rheumatology Products in the FDA’s Center for Drug Evaluation and Research.
For patients with gout, the conventional therapy is to receive drugs that lower the amount of uric acid in the blood, as, for example, the xanthine oxidase inhibitors Zyloprim (allopurinol) and Uloric (febuxostat).
Krystexxa is an enzyme that lowers uric acid levels by metabolizing it into a harmless chemical that is excreted in the urine. The drug is administered to patients every two weeks as an intravenous infusion.
Krystexxa is being approved with a Risk Evaluation and Mitigation Strategy that includes a medication guide for patients and materials for healthcare providers to communicate the risk of severe infusion and allergic reactions.
Krystexxa is manufactured by Savient Pharmaceuticals Inc. of East Brunswick, N.J.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment